vs
Side-by-side financial comparison of Cheche Group Inc. (CCG) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Cheche Group Inc. is the larger business by last-quarter revenue ($32.8M vs $20.6M, roughly 1.6× Entrada Therapeutics, Inc.). Cheche Group Inc. runs the higher net margin — 0.5% vs -84.4%, a 84.9% gap on every dollar of revenue.
Cheche Group Inc. is a leading automotive digital service provider headquartered in China. It offers integrated solutions including auto insurance intermediary services, smart auto after-sales support, and connected vehicle technology products, serving individual car owners, auto dealerships, and insurance partners across domestic and select Southeast Asian markets.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
CCG vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $32.8M | $20.6M |
| Net Profit | $153.6K | $-17.3M |
| Gross Margin | 5.7% | — |
| Operating Margin | — | -106.0% |
| Net Margin | 0.5% | -84.4% |
| Revenue YoY | — | -65.2% |
| Net Profit YoY | — | -173.8% |
| EPS (diluted) | $0.00 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $32.8M | — | ||
| Q2 25 | $26.0M | — | ||
| Q1 25 | — | $20.6M | ||
| Q4 24 | $18.6M | $37.4M | ||
| Q3 24 | — | $19.6M | ||
| Q2 24 | $36.1M | $94.7M | ||
| Q1 24 | — | $59.1M | ||
| Q4 23 | — | $41.8M |
| Q1 26 | $153.6K | — | ||
| Q2 25 | $-492.4K | — | ||
| Q1 25 | — | $-17.3M | ||
| Q4 24 | $-196.7K | $1.1M | ||
| Q3 24 | — | $-14.0M | ||
| Q2 24 | $-7.6M | $55.0M | ||
| Q1 24 | — | $23.5M | ||
| Q4 23 | — | $-9.5M |
| Q1 26 | 5.7% | — | ||
| Q2 25 | 4.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 4.3% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q1 26 | — | — | ||
| Q2 25 | -2.0% | — | ||
| Q1 25 | — | -106.0% | ||
| Q4 24 | -0.3% | -15.7% | ||
| Q3 24 | — | -110.7% | ||
| Q2 24 | -4.7% | 56.4% | ||
| Q1 24 | — | 35.7% | ||
| Q4 23 | — | 11.7% |
| Q1 26 | 0.5% | — | ||
| Q2 25 | -1.9% | — | ||
| Q1 25 | — | -84.4% | ||
| Q4 24 | -1.1% | 3.0% | ||
| Q3 24 | — | -71.7% | ||
| Q2 24 | -21.0% | 58.1% | ||
| Q1 24 | — | 39.7% | ||
| Q4 23 | — | -22.8% |
| Q1 26 | $0.00 | — | ||
| Q2 25 | $-0.01 | — | ||
| Q1 25 | — | $-0.42 | ||
| Q4 24 | $-0.00 | $-0.20 | ||
| Q3 24 | — | $-0.35 | ||
| Q2 24 | — | $1.55 | ||
| Q1 24 | — | $0.68 | ||
| Q4 23 | — | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $20.0M | $67.8M |
| Total DebtLower is stronger | $193.3K | — |
| Stockholders' EquityBook value | — | $417.3M |
| Total Assets | $203.5M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $20.0M | — | ||
| Q2 25 | $23.1M | — | ||
| Q1 25 | — | $67.8M | ||
| Q4 24 | $21.1M | $101.2M | ||
| Q3 24 | — | $78.0M | ||
| Q2 24 | $28.2M | $185.3M | ||
| Q1 24 | — | $68.4M | ||
| Q4 23 | — | $67.6M |
| Q1 26 | $193.3K | — | ||
| Q2 25 | $690.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q1 26 | — | — | ||
| Q2 25 | $47.1M | — | ||
| Q1 25 | — | $417.3M | ||
| Q4 24 | $49.1M | $428.7M | ||
| Q3 24 | — | $422.4M | ||
| Q2 24 | $48.6M | $429.9M | ||
| Q1 24 | — | $269.4M | ||
| Q4 23 | — | $242.4M |
| Q1 26 | $203.5M | — | ||
| Q2 25 | $177.3M | — | ||
| Q1 25 | — | $486.5M | ||
| Q4 24 | $177.7M | $526.3M | ||
| Q3 24 | — | $554.6M | ||
| Q2 24 | $139.3M | $582.0M | ||
| Q1 24 | — | $510.8M | ||
| Q4 23 | — | $469.2M |
| Q1 26 | — | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q2 25 | $-44.7M | — | ||
| Q1 25 | — | $-38.5M | ||
| Q4 24 | $-15.8M | $-31.6M | ||
| Q3 24 | — | $-24.3M | ||
| Q2 24 | $-1.0K | $39.8M | ||
| Q1 24 | — | $-25.5M | ||
| Q4 23 | — | $-4.0M |
| Q1 26 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-39.7M | ||
| Q4 24 | $-16.0M | $-32.2M | ||
| Q3 24 | — | $-24.9M | ||
| Q2 24 | $-1.1K | $38.8M | ||
| Q1 24 | — | $-26.4M | ||
| Q4 23 | — | $-5.0M |
| Q1 26 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -192.9% | ||
| Q4 24 | -85.9% | -86.2% | ||
| Q3 24 | — | -127.3% | ||
| Q2 24 | -0.0% | 41.0% | ||
| Q1 24 | — | -44.6% | ||
| Q4 23 | — | -11.9% |
| Q1 26 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | 1.2% | 1.7% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | 0.0% | 1.1% | ||
| Q1 24 | — | 1.4% | ||
| Q4 23 | — | 2.3% |
| Q1 26 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -27.94× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | -1.09× | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
